Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UCART019 in Relapsed/Refractory CD19+ Leukemia and Lymphoma
NCT03166878Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Jun 2017
- Primary completion
- May 2022
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of UCART019 in B-cell leukemia (BCL) and B cell lymphoma, sponsored by Chinese PLA General Hospital. Primary endpoints: Number of Participants with Severe/Adverse Events as a Measure of Safety and Tolerability at 24 weeks, Highest dose of UCART019 that is estimated to result in defined DLT at 8 weeks and 1 more. Status: unknown.
02
Drugs
UCART019
03
Conditions
B-cell leukemia (BCL)B cell lymphoma
Beyond the preview
Go deeper on NCT03166878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03166878.